Betaseron

Known as: Beta Seron, Beta-Seron 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Interferon beta is commonly used as therapeutic in the first line of therapy for multiple sclerosis. However, depending on the… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table I
Is this relevant?
Review
2010
Review
2010
Multiple sclerosis is a chronic autoimmune disease of the central nervous system for which a number of disease-modifying… (More)
Is this relevant?
2006
2006
The approved interferon beta-1b (Betaseron/Betaferon) dose is 250 microg (8 MIU) administered subcutaneously (sc) every other day… (More)
Is this relevant?
2005
2005
An open-label extension study of the phase III trial of intramuscular interferon beta-1a (IFNbeta-1a-Avonex) was conducted to… (More)
Is this relevant?
Review
2004
Review
2004
Protein- and peptide-based disease-modifying agents for multiple sclerosis (MS), including interferon beta (IFNbeta) and… (More)
Is this relevant?
1998
1998
The aim of this 1 week study was to compare the biologic effects induced by Betaseron and AVONEX using their approved dose, route… (More)
Is this relevant?
1996
1996
Production of T helper 1 and T helper 2 cytokines was investigated in peripheral blood mononuclear cells (PBMCs) from multiple… (More)
Is this relevant?
1995
1995
A new method for purifying human interferon-beta SER17 from E. coli-derived inclusion bodies has been developed. This procedure… (More)
Is this relevant?
Review
1994
Review
1994
Betaseron is a new medication that decreases the frequency and severity of exacerbations in persons with relapsing-remitting MS… (More)
Is this relevant?
1987
1987
Betaseron (beta ser17-interferon) was administered to 19 patients (17 evaluable) with advanced melanoma by two schedules… (More)
Is this relevant?